Article · 4 May 2026
ArticlePublished 11 Sep 2025
Advances in Targeted Therapy Combined with T-Cell Immunotherapy for Malignant Tumors
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
T-cell therapy has changed the treatment landscape for both haematological malignancies and solid tumors, achieving breakthroughs in areas such as relapsed/refractory acute lymphoblastic leukaemia, lymphoma, multiple myeloma, and melanoma. However, T-cell therapy still faces several limitations, including off-target effects, tumour antigen escape, and the immunosuppressive tumor microenvironment. Serious adverse reactions induced by T-cell therapy, such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immunologic escape leading to drug resistance and relapse, should also be addressed. Exploring new combination therapy approaches is considered an effective strategy to further enhance the anti-tumor effects of T-cell therapy. Chimeric antigen receptor T-cell therapy and T-cell receptor-engineered T-cell therapy are two directions of T-cell therapy. Tyrosine kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, and other targeted therapeutic drugs have been shown to have synergistic effects with T-cell therapy while reducing adverse reactions. Therefore, this article will review the combination therapy models of various targeted therapeutic drugs and T-cell therapy from the perspectives of chimeric antigen receptor T-cell therapy and T-cell receptor-engineered T-cell therapy, aiming to provide references for the basic research and quality control of T-cell immunotherapy.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Indian Journal of Pharmaceutical Sciences.
Article · 21 Apr 2026
In silico molecular docking analysis of bioactive compounds from Kappaphycus alvarezii and Gracilaria debilis against BRCA1 protein
Article · 11 Mar 2026
Trimethoprim and Sulfamethoxazole-Loaded Nanoparticles Coated With Chitosan for Intranasal Delivery to Treat Cerebral Toxoplasmosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalIndian Journal of Pharmaceutical Sciences
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Kaiqi Li”
- BylineArticles whose byline prints “Zhanshuai Wu”
- BylineArticles whose byline prints “Xian Liu”
- BylineArticles whose byline prints “Jian Ding”
- BylineArticles whose byline prints “Jiangshanwang”
- BylineArticles whose byline prints “Jian Xiao”